Value-based drug contracting software startup Lyfegen collected $8 million in Series A funding to expand its U.S. presence with a focus on specialty drugs, CEO Girisha Fernando tells Axios exclusively.
Why it matters: Specialty drugs cost vastly more than traditional medicines, often requiring special handling and administration, and account for more than half of total pharmacy spending, per a recent CVS Health report.
